Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the european medicines agency approval: Systematic review and meta-analysis

Journal of Clinical Pharmacology

Volumn 52, Issue 12, 2012, Pages 1872-1878

  Buccelletti, Francesco ^a   Iacomini, Paolo ^a   Botta, Gianfranco ^a   Marsiliani, Davide ^a   Carroccia, Annarita ^a   Gentiloni Silveri, Nicolò ^a   Franceschi, Francesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

atrial fibrillation; cardioversion; efficacy; safety; Vernakalant

Indexed keywords

AMIODARONE; VERNAKALANT;

ARTICLE; BRADYCARDIA; CARDIOVERSION; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUG APPROVAL; EUROPEAN UNION; GOVERNMENT REGULATION; HUMANS; MEMBRANE TRANSPORT MODULATORS; PYRROLIDINES;

EID: 84868610768     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011426876     Document Type: Article

References (35)

1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001 ; 86: 516-521
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 ; 285: 2370-2375
3. Camm AJ, Kirchof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010 ; 12: 1360-1420
4. Stiel IG, Clement CM, Perry JJ, et al. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM. 2010 ; 12: 181-191
5. Decker WW, Smarts PA, Vaidyanathan L, et al. A prospective, randomized trial of an emergency department observation unit for acute onset atrial fibrillation. Ann Emerg Med. 2008 ; 52: 322-328
6. Nichol G, McAlister F, Pham B, et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart. 2002 ; 87: 535-543
7. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010 ; 375: 1212-1223
8. European Medicines Agency. Assessment Report for Brinavess. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/001215/WC500097150.pdf. Accessed May 23, 2011.
9. US Food and Drug Administration, Center for Drug Evaluation and Research. Minutes of the meeting of the Cardio-Renal Advisory Committee, 14November2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4327b1-02-fda-backgrounder. pdf. Accessed May 23, 2011.
10. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005 ; 16: 1227-1238
11. Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant, a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs. 2008 ; 17: 805-810
12. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007 ; 50: 35-40
13. Duggan ST, Scott LJ. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation. Drugs. 2011 ; 71: 237-252
14. Orth PM, Hesketh JC, Mak CK, et al. RSD1235 blocks late Ina and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res. 2006 ; 70: 486-496
15. Higgins J, Green S Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. New York: John Wiley ; 2011 :
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996 ; 17: 1-12
17. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G. Tips for learners of evidence-based medicine, 3: measures of observer variability (kappa statistic). CMAJ. 2004 ; 171: 1369-1373
18. Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. Am J Epidemiol. 1987 ; 126: 161-169
19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 ; 339: b2700
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 ; 22: 719-748
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 ; 7: 177-188
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 ; 315: 629-634
23. A phase II/III tolerance and efficacy study of RSD1235 in patients with atrial flutter (scene 2). http://clinicaltrials.gov/ct2/show/NCT00476112?term= vernakalant&rank=2. Accessed May 23, 2011.
24. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004 ; 44: 2355-2361
25. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 ; 117: 1518-1525
26. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009 ; 2: 652-659
27. Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010 ; 106: 1277-1283
28. Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010 ; 159: 1095-1101
29. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011 ; 57: 313-321
30. A phase IIIb study of vernakalant injection in patients with recent onset symptomatic atrial fibrillation (ACT V). http://clinicaltrials.gov/ct2/show? term=vernakalant&rank=3. Accessed May 23, 2011.
31. Cardiome. Cardiome announces suspension of enrollment in ACT 5 trial, 21October2010. http://cardiome.com/wordpress/?p=563Accessed May 23, 2011.
32. Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 ; 49: 17-29
33. Kochiadakis GE, Igoumenidis NE, Simantirakis EN, et al. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. Pacing Clin Electrophysiol. 1998 ; 21: 2475-2479
34. Alp NJ, Bell JA, Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart. 2000 ; 84: 37-40
35. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998 ; 316: 61-66